Wei-Che Ko
Triamcinolone Acetonide(Wei-Che Ko)은 Diabetic Macular Edema 표적 치료제로, Skin Inflammation; Allergic Contact Dermatitis 영역에서 개발·상용화 중입니다. 작용기전: targeting of STING-TBK1 signaling. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 9.8% (ClinicalTrials.gov NCT03520387). 차별점: novel intravitreal therapeutic options.
Diabetic Macular Edema
Skin Inflammation; Allergic Contact Dermatitis
Recruiting
car thickness changes
novel intravitreal therapeutic options
targeting of STING-TBK1 signaling
apoptosis, pyroptosis and necroptosis activation, consistent with a PANoptosis-like phenotype
biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l
resistance to salivary shear flow, and effective barrier function against bacterial penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Wei-Che Ko
Triamcinolone Acetonide(Wei-Che Ko)은 Diabetic Macular Edema 표적 치료제로, Skin Inflammation; Allergic Contact Dermatitis 영역에서 개발·상용화 중입니다. 작용기전: targeting of STING-TBK1 signaling. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 9.8% (ClinicalTrials.gov NCT03520387). 차별점: novel intravitreal therapeutic options.
Diabetic Macular Edema
Skin Inflammation; Allergic Contact Dermatitis
Recruiting
car thickness changes
novel intravitreal therapeutic options
targeting of STING-TBK1 signaling
apoptosis, pyroptosis and necroptosis activation, consistent with a PANoptosis-like phenotype
biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l
resistance to salivary shear flow, and effective barrier function against bacterial penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.